南加州大学凯克医学院的研究团队发现,实验性药物cinaciguat在为期两周的治疗中,成功逆转了老年大鼠肝细胞的衰老特征 1。该研究结果表明,这种治疗能使与阿尔茨海默病相关的淀粉样蛋白β水平下降约50%,并将低密度脂蛋白(LDL)胆固醇恢复至年轻动物的水平 1。这项成果揭示了肝窦内皮细胞与肝细胞之间一种此前未知的信号传导通路,即通过激活可溶性鸟苷酸环化酶释放HB-EGF生长因子,从而协调肝细胞清除血液中的有害物质 1。
通讯作者Laurie Deleve (MD, PhD)指出:“与其尝试让药物穿过极其困难的血脑屏障,我们或许可以将药物直接靶向肝脏……” 1。第一作者Sam de Leve (MA)参与了这项发表于《生物化学杂志》(Journal of Biological Chemistry)的研究 1。然而,研究人员强调目前的结果仅在动物实验中得到证实,尚未在人类中确认其有效性,未来仍需进行进一步的转化研究以验证该疗法对人类的潜在价值 1。
Researchers at the Keck School of Medicine of USC have demonstrated that an experimental drug can reverse signs of aging in liver cells, significantly reducing levels of amyloid beta—a protein associated with Alzheimer’s disease—and restoring cholesterol profiles to youthful standards. 1 The study focused on elderly rats treated for two weeks with cinaciguat, a compound that targets specific signaling pathways within the liver. 1 Following this short-term treatment, the animals showed approximately 50% lower levels of amyloid beta compared to untreated counterparts, while their low-density lipoprotein (LDL) cholesterol levels returned to those observed in young animals. 1
The findings reveal a previously unknown communication mechanism between liver sinusoidal endothelial cells and hepatocytes, suggesting that targeting the liver could offer new strategies for preventing both Alzheimer’s disease and cardiovascular conditions. 1 By activating soluble guanylate cyclase, the drug triggers the release of HB-EGF growth factor, which coordinates the liver’s ability to clear harmful substances from the blood. 1 Laurie DeLeve, MD, PhD, who served as the senior author of the paper published in the Journal of Biological Chemistry, emphasized the potential advantage of this approach over traditional methods: “Rather than trying to get a drug through the blood-brain barrier, which is obnoxiously difficult, we could direct drugs to the liver...” 1 Sam de Leve, MA, was the first author on the study, which carries the DOI 10.1016/j.jbc.2026.113608. 1
Despite these promising results, the current evidence remains limited to animal models, and further translational research is necessary to verify whether these benefits hold true in humans. 1 The work was conducted in Los Angeles, with the key findings reported on November 2, 2026. 1
评论
还没有评论,欢迎留下第一条。